The following transactions relate to bond investments of Livermore Laboratories. The company's fiscal year ends on December 31. Livermore uses the straight-line method to determine interest. 2024 July 1 Purchased $30 million of Bracecourt Corporation 10% debentures, due in 20 years (June 30, 2844), for $29.1 million. Interest is payable on January 1 and July 1 of each year. October 1 Purchased $44 million of 12% Fram Pharmaceuticals debentures, due May 31, 2034, for $46,784,000 plus accrued interest. Interest is payable on June 1 and December 1 of each year. December 1 Received interest on the Frann bonds. December 31 Accrued interest. 2025 January 1 Received interest on the Bracecourt bonds. June 1 Received interest on the Frann bonds. July 1 Received interest on the Bracecourt bonds. September 1 Sold $22.0 million of the Franm bonds at 102 plus accrued interest. December 1 Received interest on the remaining Frame bonds. December 31 Accrued interest. 2026 January 1 Received interest on the Bracecourt bonds. February 28 Sold the remainder of the Franm bonds at 103 plus accrued interest. December 31 Accrued interest. Required: 1. Prepare the appropriate journal entries for these long-term bond investments. 2. By how much will Livermore Labs' earnings increase in each of the three years as a result of these investments? (Ignore income. taxes) Complete this question by entering your answers in the tabs below. Required 1 Required 2 Prepare the appropriate journal entries for these long-term bond investments. Note: If no entry is required for a transaction/event, select "No journal entry required" in the first account field. Do not round your